Back to News
Market Impact: 0.3
10x Genomics, Inc. Reports Third Quarter 2026 Financial Results and Raises Full Year Revenue Guidance
Source: Nasdaq
Corporate EarningsCompany Fundamentals
10x Genomics reported third-quarter 2026 revenue of $150.7 million, up 1% from $149.0 million in the year-earlier quarter. Gross margin was 75%; the provided article text ends before giving the comparison or further results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
TXG0.15
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Equity Research Automation Statistics: A 2026 Evidence Check